Mucous membrane pemphigoid MMP is an otoimmun, cronic, inflamatuary, blastering disease. Its clinical presentation may cover the oral mucosa, the ocular mucosa, the other mucous membrane and the skin. Healing of the lesions, except the lesions of oral mucosa, occurs with skar tissue which may cause blindness when involves the conjuctiva. Ocular mucosa is the most involved mucousa after oral mucosa. Ophtalmologic consultation and following up of this patients is necessary. A multidisciplinary approach is essential in the managenet of MMP. Early recognition and treatment may decrease disease-related complications. Patients who have disease occuring in only oral mucosa are defined as “low risk” patients. Nowadays, low group patients can be controlled by topical corticosteroids TC , which have proved to be highly efficient and to cause fewer adverse effects compared with systemic corticosteroids. The effect of TC depends on its potency, concentration, pharmaceutical form and contact time between the drug and lesion. The medical status of the patient, the severity of the oral lesions, the extensiveness of the lesion and the experience of the clinician affect the choice of the special formulation, treatment regime and the potency of TCs which will be used in treatment of MMP limited in the oral mucosa. In this report clinical view of a 59 years old female patient with MMP who is treated with corticosteroids is presented
3. Sami N, Bhol KC, Ahmed AR.
Intravenous Immunoglobulin Therapy in
Patients with Multiple Mucosal Involvement in
Mucous Membrane Pemphigoid.Clin Immunology 2002; 102: 59-67
4. Marx RE, Stern D.Immune-Based
Diseases.In:editor Bywaters LC.Oral and
Maxillofacial Pathology.A Rationale for
Diagnosis and Treatment.2003.Chapter 3: 148-
53
5. Leao JC, Ingafou M,Khan A,Scully C,
Porter S.Desquamative gingivitis: retrospective
analysis of disease associations of a large
cohort.Oral Dis 2008; 14: 556-60
6. MOSTAFA MI, HASSIB NF,NEMAT
AH. Case Report.Oral mucous membrane
pemphigoid in a 6-year-old boy: diagnosis,
treatment and 4 years follow-up.Int J of
Paediatric Dentistry 2009; 76-9
7. Thorne JE, Anhalt GJ, Jabs DA.
Mucous membrane pemphigoid and pseudopemphigoid.Ophtalmol 2004; 111: 45-52
8. Ahmed AR, Kurgis BS, Rogers III RS.
Cicatricial pemphigoid. J Am Acad Dermatol
1991; 24: 987-1001
15. Alkan A, Gunhan O ,Otan F.A.
Clinical study of oral mucous membrane
pemphigoid. J Int Med Res 2003; 31: 340-4
16. Helander SD, Rogers III RS.The
sensitivity and specificity of direct
immunofluorescence testing in disorders of
mucous membranes. J Am Acad Dermatol
1994; 30: 65-75
17. Scott JE, Ahmed AR. The blistering
diseases. Med Clin North Am 1998; 82: 1239-
83
18. Suresh L and Kumar V. Significance
of IgG4 in the diagnosis of mucous membrane
pemphigoid. Oral Surg Oral Med Oral Pathol
2007; 104: 359-62
19. Neff AG, Turner M, Mutasim DF.
Treatment strategies in mucous membrane
pemphigoid. Ther Clin Risk Manag 2008; 4:
617-26
20. Higgins GT, Allan RB, Hall R, Field
EA, Kaye SB. Development of ocular disease
in patients with mucous membrane pemphigoid involving the oral mucosa. Br J
Ophtalmol 2006; 90: 964- 67
21. Ciarrocca KN,Greenberg MS.A
retrospective study of the management of oral
mucous membrane pemphigoid with dapsone.
Oral Surg Oral Med Oral Pathol 1999; 88: 159-
63
22. Arash A, Shirin L.The management of
oral mucous membrane pemphigoid with
dapsone and topical corticosteroid.J Oral
Pathol Med 2008; 37: 341-44
23. Gonzalez-Moles MA, Scully C.
Vesiculo-erosive Oral Mucosal DiseaseManagement with Topical Corticosteroids: (1)
Fundamental Principles and Specific Agents
Abailable. J Dent Res 2005; 84:294-301
24. Heffernan MP, Bentley DD.
Successful Treatment of Mucous Membrane
Pemphigoid With Infliximab. Arch Dermatol
2006; 142: 1268-70
25. Kayalap S.O. Rasyonel Tedavi
Ynünden Tıbbi Farmakoloji. 10. Baskı Hacettepe – Tıp. 2002; 1230-50
Mükoz membran pemfigoid MMP kronik, enflamatuar, subepiteliyal veziküllo-büllöz bir otoimmün hastalıktır. Hastalığın lezyonları oral mukozayı, oküler mukozayı,diğer muköz membranları ve deriyi kapsayabilir. Ağız lezyonların haricindeki lezyonların iyileşmesi skarla sonuçlanır. Göz tutulumu körlükle sonuçlanabilir. Oral mukozadan sonra en sık tutulan bölge konjuktiva olduğu için bu hastalarda mutlaka oftalmolojik konsültasyon ve takip yapılmalıdır. MMP’in tedavisi multdisipliner bir yaklaşım gerektirir. Erken teşhis ve tedavisi hastalığa bağlı komplikasyonları önleyebilir. Lezyonları sadece ağız içinde olan hastalar “düşük riskli” hasta grubu olarak tanımlanır. Günümüzde düşük riskli hasta grubu sistemik kortikosteroidlere göre daha etkili ve daha az yan etkileri olan topikal kortikosteroidlerle tedavi edilebilir. TS’lerin etkinliği ilacın gücüne, konsantrasyonuna, ilacın farmasötik şekline ve ilaç – lezyon temas süresine bağlıdır. Hastanın medikal durumu, ağız içi lezyonların şiddeti, tutulumun yaygınlığı ve hekimin deneyimi oral mukozada sınırlı kalan MMP’nin tedavisinde kullanılacak TS’nin potensinin, özel formülasyonun ve tedavi rejiminin seçimini etkiler. Bu raporda 59 yaşında MMP’li bir kadın hastanın kliniği ve topikal steroidlerle yapılan tedavisi sunulmaktadır.
3. Sami N, Bhol KC, Ahmed AR.
Intravenous Immunoglobulin Therapy in
Patients with Multiple Mucosal Involvement in
Mucous Membrane Pemphigoid.Clin Immunology 2002; 102: 59-67
4. Marx RE, Stern D.Immune-Based
Diseases.In:editor Bywaters LC.Oral and
Maxillofacial Pathology.A Rationale for
Diagnosis and Treatment.2003.Chapter 3: 148-
53
5. Leao JC, Ingafou M,Khan A,Scully C,
Porter S.Desquamative gingivitis: retrospective
analysis of disease associations of a large
cohort.Oral Dis 2008; 14: 556-60
6. MOSTAFA MI, HASSIB NF,NEMAT
AH. Case Report.Oral mucous membrane
pemphigoid in a 6-year-old boy: diagnosis,
treatment and 4 years follow-up.Int J of
Paediatric Dentistry 2009; 76-9
7. Thorne JE, Anhalt GJ, Jabs DA.
Mucous membrane pemphigoid and pseudopemphigoid.Ophtalmol 2004; 111: 45-52
8. Ahmed AR, Kurgis BS, Rogers III RS.
Cicatricial pemphigoid. J Am Acad Dermatol
1991; 24: 987-1001
15. Alkan A, Gunhan O ,Otan F.A.
Clinical study of oral mucous membrane
pemphigoid. J Int Med Res 2003; 31: 340-4
16. Helander SD, Rogers III RS.The
sensitivity and specificity of direct
immunofluorescence testing in disorders of
mucous membranes. J Am Acad Dermatol
1994; 30: 65-75
17. Scott JE, Ahmed AR. The blistering
diseases. Med Clin North Am 1998; 82: 1239-
83
18. Suresh L and Kumar V. Significance
of IgG4 in the diagnosis of mucous membrane
pemphigoid. Oral Surg Oral Med Oral Pathol
2007; 104: 359-62
19. Neff AG, Turner M, Mutasim DF.
Treatment strategies in mucous membrane
pemphigoid. Ther Clin Risk Manag 2008; 4:
617-26
20. Higgins GT, Allan RB, Hall R, Field
EA, Kaye SB. Development of ocular disease
in patients with mucous membrane pemphigoid involving the oral mucosa. Br J
Ophtalmol 2006; 90: 964- 67
21. Ciarrocca KN,Greenberg MS.A
retrospective study of the management of oral
mucous membrane pemphigoid with dapsone.
Oral Surg Oral Med Oral Pathol 1999; 88: 159-
63
22. Arash A, Shirin L.The management of
oral mucous membrane pemphigoid with
dapsone and topical corticosteroid.J Oral
Pathol Med 2008; 37: 341-44
23. Gonzalez-Moles MA, Scully C.
Vesiculo-erosive Oral Mucosal DiseaseManagement with Topical Corticosteroids: (1)
Fundamental Principles and Specific Agents
Abailable. J Dent Res 2005; 84:294-301
24. Heffernan MP, Bentley DD.
Successful Treatment of Mucous Membrane
Pemphigoid With Infliximab. Arch Dermatol
2006; 142: 1268-70
25. Kayalap S.O. Rasyonel Tedavi
Ynünden Tıbbi Farmakoloji. 10. Baskı Hacettepe – Tıp. 2002; 1230-50